20. Janjigian YY, Akihito Kawazoe, Jianming Xu, et al. Health-related quality of life (HRQOL) with pembrolizumab (pembro) plus trastuzumab (tras) and chemotherapy (chemo) in first-line HER2-positive (HER2+) advanced gastric cancer: KEYNOTE...
(pembro)/trastuzumab and chemotherapy (chemo) provided superior PFS, and improved ORR with durable responses vs placebo (pbo)/trastuzumab and chemo in unresectable, HER2+ metastatic gastric or gastroesophageal junction (mG/GEJ)...
[3] Yamaguchi K, Bang YJ, Iwasa S, et al. Trastuzumab deruxtecan (T-DXd; DS-8201) in pati ents with HER2–positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Final overall survival (OS) results from a randomized, multicenter, open-label, phase 2 study (DESTINY-Gas...
[11]JOHANSSON A L V, TREWIN C B, HJERKIND K V, et al. Breast cancer-specific survival by clinical subtype after 7 years follow-up of young and elderly women in a nationwide cohort [J]. Int J Cancer, 2019, 144(6): 1251-1261. [12]PARTRIDGE A H, HUGHES M E, WARNER E T, et...
Treatment with anti-programmed cell death protein 1 (PD-1) therapy and chemotherapy prolongs the survival of patients with unresectable advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma. The benefit from anti-PD-1 therapy is enriched in patients with programmed cell death...
Abstract P4-15-11: Advanced HER2 positive breast cancer treated with trastuzumab: Is combination with chemotherapy always needed? Randomized phase III trial SAKK 22/99 TChemo) versus the upfront combination of T and chemo (TChemo) in patients with HER2+ advanced breast cancer.Materials and ...
The overall response rate (ORR) and median progression-free survival (PFS) were 30.1% and 7.4 months, respectively6. In the SOLTI-1805 TOT-HER3 window-of-opportunity trial Part A, a single dose of HER3-DXd (6.4 mg/kg) was evaluated in 78 patients with untreated early-stage HR+/HER2-...
In addition to the OS improvement, the pre-specified interim analysis by independent data monitoring committee review also highlighted a statistically significant and clinically meaningful improvement in progression-free survival (PFS) and overall response rate (ORR) in patient...
Margetuximab versus trastuzumab in patients with previously treated HER2-positive advanced breast cancer(SOPHIA):final overall survival results from a randomized phase 3 trial[J]. J Clin Oncol,2023,41(2):198-205. [41] MARKHAM A. Margetuximab:first approval[J]. Drugs, 2021,81(5):599-604....
[4]Kang YJ, Han W, Park S, et al. Outcome following sentinel lymph node biopsyguided decisions in breast cancer patients with conversion from positive to negative axillary lymph nodes after neoadjuvant chemotherapy. Breast Cancer Res Treat. 2017 Nov;166(2):473-480. ...